Zevra Therapeutics to Present Top-Line Data from the Phase 2 Clinical Trial of KP1077 for Idiopathic Hypersomnia at Sleep Europe 2024
Zevra Therapeutics Inc ZVRA
News
FDA Approves Zevra's Miplyffa for Niemann-Pick Disease Type C — 2nd Update
FDA Approves Zevra's Miplyffa for Niemann-Pick Disease Type C — Update
Zevra Therapeutics’ MIPLYFFA™ (arimoclomol) Receives U.S. FDA Approval as Treatment for Niemann-Pick Disease Type C
FDA Approves Zevra's Miplyffa for Niemann-Pick Disease Type C
Zevra Therapeutics Presented New Data for Arimoclomol and OLPRUVA® (Sodium Phenylbutyrate) at the Society for the Study of Inborn Errors of Metabolism (SSIEM) 2024 Annual Symposium
Zevra Therapeutics to Participate at Upcoming Investor Conferences
Zevra Therapeutics Reports Second Quarter 2024 Financial Results and Corporate Highlights
Zevra Therapeutics Announces Pricing of Underwritten Offering of Common Stock
Zevra Therapeutics Announces Proposed Public Offering of Common Stock
Zevra Therapeutics to Present at Canaccord Genuity’s 44th Annual Growth Conference
Zevra Shares Rally Premarket After FDA Panel Backs Arimoclomol
Zevra: FDA Advisory Committee Votes Favorably on Arimoclomol for NPC Patients
FDA Advisory Committee Votes Favorably that the Data Support Arimoclomol as Effective Treatment for Patients with Niemann-Pick Disease Type C
Zevra Therapeutics to Report Second Quarter 2024 Financial Results
Zevra Announces FDA Advisory Committee Meeting to Review Arimoclomol for the Treatment of Niemann-Pick Disease Type C
Zevra Therapeutics Shares Fall After FDA Extends Arimoclomol Review
FDA Extends Review of Zevra's Arimoclomol by Three Months
Xoma to Make $1 Million Milestone Payment to LadRx After FDA Accepts Zevra Application for Arimoclomol
Zevra Therapeutics Refiles Arimoclomol Application With FDA
United States